Drug Shortage Report for TAKHZYRO
| Report ID | 151175 |
| Drug Identification Number | 02480948 |
| Brand name | TAKHZYRO |
| Common or Proper name | Lanadelumab Injection |
| Company Name | TAKEDA CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | LANADELUMAB |
| Strength(s) | 300MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | 2 mL Vial |
| ATC code | B06AC |
| ATC description | |
| Reason for shortage | Delay in shipping of the drug. |
| Anticipated start date | 2021-12-15 |
| Actual start date | 2021-12-15 |
| Estimated end date | 2022-01-14 |
| Actual end date | 2022-01-12 |
| Shortage status | Resolved |
| Updated date | 2022-01-13 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 22 ADELAIDE STREET WEST TORONTO, ONTARIO CANADA M5H 4E3 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v8 | 2022-01-13 | French | Compare |
| v7 | 2022-01-13 | English | Compare |
| v6 | 2022-01-06 | French | Compare |
| v5 | 2022-01-06 | English | Compare |
| v4 | 2021-12-16 | English | Compare |
| v3 | 2021-12-15 | French | Compare |
| v2 | 2021-12-15 | English | Compare |
| v1 | 2021-12-15 | English | Compare |
Showing 1 to 8 of 8